Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03153891 · ClinicalTrials.gov registry record · NA

Nature as a Buffer Among People With Chronic Pain

A NA study of Chronic Pain, sponsored by Cornell University.

Completed
Registry status
NA
Development phase
23
Enrollment target
1
Study location

NCT03153891: Completed NA study of Chronic Pain, sponsored by Cornell University.

NCT03153891 is a NA study of Chronic Pain that has completed, run by Cornell University. The registered enrollment target is 23 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03153891, a NA study of Chronic Pain, has completed, sponsored by Cornell University.

COMPLETED
Registry status
NA
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

This randomized controlled trial examines the effect of nature exposure on pain intensity levels among older adults who experience chronic pain. Investigators examine the effects of nature on: the experience of chronic pain, on pain catastrophizing, and on attention restoration.

Primary Outcome

rating of pain intensity, on scale of 1-10

Conditions Studied

Interventions

  • OTHER Built Environment
  • OTHER Natural Environment

Study Locations (1)

New York

  • Cornell University - Ithaca

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2016-07-01
Est. Completion 2018-06
Phase NA
Cornell University

66 total trials

What the finished NCT03153891 record still lists

NCT03153891 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Chronic Pain appearing as the primary indexed condition, and to 2 interventions - of which Built Environment is the first listed.

NCT03153891 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT03153891 about?

NCT03153891 is a clinical study titled "Nature as a Buffer Among People With Chronic Pain". This randomized controlled trial examines the effect of nature exposure on pain intensity levels among older adults who experience chronic pain. Investigators examine the effects of nature on: the experience of chronic pain, on pain catastrophizing, and on attention restoration.

What is the current status of trial NCT03153891?

This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2016-07-01. Estimated completion is 2018-06.

What conditions does trial NCT03153891 study?

This clinical trial studies the following conditions: Chronic Pain.

What interventions are being tested in trial NCT03153891?

The interventions under investigation include: Built Environment (OTHER), Natural Environment (OTHER).

Who is sponsoring clinical trial NCT03153891?

This trial is sponsored by Cornell University, which has 66 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03153891 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03153891's enrollment target sits among peer trials

23 266th of 301 higher than 35 of 301 other Chronic Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03153891, the US trial registry maintained by the National Library of Medicine. NCT03153891 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.